rofecoxib has been researched along with Asthma in 14 studies
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin (ASA) and several other nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase (COX) enzyme both isoforms 1 and 2, and can precipitate asthmatic attacks in aspirin-induced asthmatics." | 9.12 | Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. ( Dal Negro, R; Guerriero, M; Micheletto, C; Tognella, S, 2006) |
| "In a subset of patients with asthma, aspirin and several other non-steroidal anti-inflammatory drugs (NSAID) that inhibit simultaneously cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) precipitate dangerous asthmatic attacks." | 9.09 | Safety of a specific COX-2 inhibitor in aspirin-induced asthma. ( Bochenek, G; Mejza, F; Nagraba, K; Nizankowska, E; Swierczynska, M; Szczeklik, A, 2001) |
| "The goal of this study was to determine whether rofecoxib cross-reacts in aspirin-sensitive patients with asthma." | 9.09 | Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. ( Simon, RA; Stevenson, DD, 2001) |
| "To review the safety of cyclooxygenase-2 (COX-2) inhibitors in asthma patients with aspirin hypersensitivity." | 8.82 | Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. ( Fernández, C; West, PM, 2003) |
| " Clinical data show that mixed COX-1/COX-2 inhibitors such as aspirin, but not COX-2 selective inhibitors such as rofecoxib, induce bronchoconstriction and asthma in sensitive individuals." | 7.74 | COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. ( Harrington, LS; Lucas, R; McMaster, SK; Mitchell, JA; Moreno, L; Scadding, G; Warner, TD, 2008) |
| "In 5 to 10% of adult patients with asthma, aspirin (acetylsalicylic acid [ASA]) and most other nonsteroidal anti-inflammatory drugs (NSAIDs) precipitate acute asthmatic attacks." | 7.71 | Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. ( Alfaya, T; Berges, P; Camacho, E; García-Rodriguez, R; Hinojosa, M; Iscar, A; Martín-García, C, 2002) |
| "Aspirin (ASA) and several other nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase (COX) enzyme both isoforms 1 and 2, and can precipitate asthmatic attacks in aspirin-induced asthmatics." | 5.12 | Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. ( Dal Negro, R; Guerriero, M; Micheletto, C; Tognella, S, 2006) |
| " Three subjects with multiple-drug induced urticaria complained of a generalized reaction after challenge (Two due to celecoxib and one due to meloxicam)." | 5.11 | Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. ( Antonicelli, L; Bilò, MB; Bonadonna, P; Crivellaro, MA; Dama, AR; Schiappoli, M; Senna, G, 2004) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by progressive sinusitis, nasal polyposis, and asthma that begins and continues in the absence of exposure to aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)." | 5.11 | Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. ( Simon, RA; Stevenson, DD; Woessner, KM, 2004) |
| "To compare the clinical tolerance to rofecoxib and valdecoxib in patients who previously developed urticaria and angioedema while taking classic NSAIDs." | 5.11 | Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. ( Caballero-Fonseca, F; Capriles-Hulett, A; Sánchez-Borges, M, 2005) |
| "In a subset of patients with asthma, aspirin and several other non-steroidal anti-inflammatory drugs (NSAID) that inhibit simultaneously cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) precipitate dangerous asthmatic attacks." | 5.09 | Safety of a specific COX-2 inhibitor in aspirin-induced asthma. ( Bochenek, G; Mejza, F; Nagraba, K; Nizankowska, E; Swierczynska, M; Szczeklik, A, 2001) |
| "The goal of this study was to determine whether rofecoxib cross-reacts in aspirin-sensitive patients with asthma." | 5.09 | Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. ( Simon, RA; Stevenson, DD, 2001) |
| "To review the safety of cyclooxygenase-2 (COX-2) inhibitors in asthma patients with aspirin hypersensitivity." | 4.82 | Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. ( Fernández, C; West, PM, 2003) |
| "Selective pharmacological inhibition of COX-2 during the challenge phase worsens airway function in the ovalbumin -induced murine model of acute asthma." | 3.75 | [A cyclooxygenase-2 selective inhibitor worsens respiratory function and enhances mast cell activity in ovalbumin-sensitized mice]. ( de Mora, F; Marco, A; Pérez, M; Picado, C; Torres, R, 2009) |
| " Clinical data show that mixed COX-1/COX-2 inhibitors such as aspirin, but not COX-2 selective inhibitors such as rofecoxib, induce bronchoconstriction and asthma in sensitive individuals." | 3.74 | COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. ( Harrington, LS; Lucas, R; McMaster, SK; Mitchell, JA; Moreno, L; Scadding, G; Warner, TD, 2008) |
| "Rofecoxib appears to be a safe alternative drug among atopic individuals, antibiotic-hypersensitive individuals, and individuals who experienced adverse cutaneous reactions to more than 1 class of NSAIDs, but it is less safe among chronic urticaria patients." | 3.73 | Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. ( Colanardi, MC; Ferrannini, A; Nettis, E; Tursi, A, 2005) |
| "In 5 to 10% of adult patients with asthma, aspirin (acetylsalicylic acid [ASA]) and most other nonsteroidal anti-inflammatory drugs (NSAIDs) precipitate acute asthmatic attacks." | 3.71 | Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. ( Alfaya, T; Berges, P; Camacho, E; García-Rodriguez, R; Hinojosa, M; Iscar, A; Martín-García, C, 2002) |
| " One hundred twenty-seven subjects with history of adverse reaction to ASA/NSAIDs received oral challenges with nimesulide, 61 subjects were challenged with meloxicam, 51 subjects were challenged with rofecoxib, and 37 subjects were challenged with all three drugs." | 2.71 | Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. ( Bavbek, S; Celik, G; Misirligil, Z; Mungan, D; Ozer, F, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harrington, LS | 1 |
| Lucas, R | 1 |
| McMaster, SK | 1 |
| Moreno, L | 1 |
| Scadding, G | 1 |
| Warner, TD | 1 |
| Mitchell, JA | 1 |
| Torres, R | 1 |
| Pérez, M | 1 |
| Marco, A | 1 |
| Picado, C | 2 |
| de Mora, F | 1 |
| Valero, A | 1 |
| Baltasar, M | 1 |
| Enrique, E | 1 |
| Pau, L | 1 |
| Dordal, MT | 1 |
| Cisteró, A | 1 |
| Martí, E | 1 |
| Inoue, K | 1 |
| Takano, H | 1 |
| Kawahito, Y | 1 |
| Sano, H | 1 |
| Yoshikawa, T | 1 |
| West, PM | 1 |
| Fernández, C | 1 |
| Bavbek, S | 1 |
| Celik, G | 1 |
| Ozer, F | 1 |
| Mungan, D | 1 |
| Misirligil, Z | 1 |
| Senna, G | 1 |
| Bilò, MB | 1 |
| Antonicelli, L | 1 |
| Schiappoli, M | 1 |
| Crivellaro, MA | 1 |
| Bonadonna, P | 1 |
| Dama, AR | 1 |
| Woessner, KM | 1 |
| Simon, RA | 2 |
| Stevenson, DD | 2 |
| Nettis, E | 1 |
| Colanardi, MC | 1 |
| Ferrannini, A | 1 |
| Tursi, A | 1 |
| Sánchez-Borges, M | 1 |
| Caballero-Fonseca, F | 1 |
| Capriles-Hulett, A | 1 |
| Micheletto, C | 1 |
| Tognella, S | 1 |
| Guerriero, M | 1 |
| Dal Negro, R | 1 |
| Szczeklik, A | 1 |
| Nizankowska, E | 1 |
| Bochenek, G | 1 |
| Nagraba, K | 1 |
| Mejza, F | 1 |
| Swierczynska, M | 1 |
| Martín-García, C | 1 |
| Hinojosa, M | 1 |
| Berges, P | 1 |
| Camacho, E | 1 |
| García-Rodriguez, R | 1 |
| Alfaya, T | 1 |
| Iscar, A | 1 |
1 review available for rofecoxib and Asthma
| Article | Year |
|---|---|
Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Cyclooxygenase 2; Drug Hypersen | 2003 |
7 trials available for rofecoxib and Asthma
| Article | Year |
|---|---|
Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase In | 2004 |
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celec | 2004 |
Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cross Reactions; Cyclooxygenase Inhibitors | 2004 |
Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Cyclooxygenase Inhibitors | 2005 |
Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma.
Topics: Adult; Aspirin; Asthma; Bronchoconstriction; Cyclooxygenase 2 Inhibitors; Female; Forced Expiratory | 2006 |
Safety of a specific COX-2 inhibitor in aspirin-induced asthma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cross-Over Studies; Cyclooxygenase | 2001 |
Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cross Reactions; Cyclooxygenase Inhibitors | 2001 |
6 other studies available for rofecoxib and Asthma
| Article | Year |
|---|---|
COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Animals; Aspirin; | 2008 |
[A cyclooxygenase-2 selective inhibitor worsens respiratory function and enhances mast cell activity in ovalbumin-sensitized mice].
Topics: Animals; Asthma; Cyclooxygenase 2 Inhibitors; Lactones; Mast Cells; Mice; Mice, Inbred BALB C; Ovalb | 2009 |
NSAID-sensitive patients tolerate rofecoxib.
Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Controlled Cli | 2002 |
Cyclooxygenase-2 inhibitors in aspirin-induced asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit | 2003 |
Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Cyclooxygenase Inhibitors; Drug Hypers | 2005 |
Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase Inhibitors; Fe | 2002 |